Terns Achieves Primary Endpoint And All Secondary Endpoints In Phase 2a DUET Trial Of THR-β Agonist TERN-501 In NASH
Portfolio Pulse from Happy Mohamed
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) reported positive top-line results from the Phase 2a DUET clinical trial of TERN-501, a treatment for non-alcoholic steatohepatitis (NASH). The trial achieved its primary endpoint with significant reductions in liver fat content. TERN-501 also demonstrated improvements in plasma lipid parameters and was well-tolerated with no gastrointestinal and no cardiovascular safety signals. The combination of TERN-501 and TERN-101 also showed promising results.
August 08, 2023 | 9:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Terns Pharmaceuticals' positive trial results for TERN-501 could boost investor confidence and potentially lead to a short-term increase in the company's stock price.
Positive clinical trial results often lead to increased investor confidence as they indicate progress in the company's product pipeline and potential future revenue streams. This could lead to increased demand for the company's stock, potentially driving up the price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100